Ology Bioservices was acquired by National Resilience, Inc. (Resilience) in April of 2021. For more information on available services, please visit the Resilience website at https://resilience.com. History: Ology Bioservices was founded in 1999 as an integrated biopharmaceutical company with a focus on development and manufacturing as well as having expertise in preclinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. From its early beginnings, the company’s growth was fueled through grants and contracts from both industry and several U.S. Government (USG) agencies (NIH, DoD, NCI, BARDA). Today, the company has grown to over 185 employees located in several offices across the U.S. On March 30, 2013, the Department of Defense (DoD) awarded the company and its team of partners and collaborators a contract to provide all of the core services necessary to establish a Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) facility dedicated to meeting the specific needs of the DoD. The 10-year, $400+ million contract had a base period goal for the construction of an 183,000-square-foot, state-of-the-art, BSL-3, single-use facility that the company now occupies and operates. Ology Bio recently developed and acquired proprietary platform technologies that are used in the production of biologic products including proteins, monoclonal antibodies, and vaccines.